 |
Doug Macron is the editor of GenomeWeb's Gene Silencing News. He covers research and therapeutic applications of RNAi, miRNA, and other gene-silencing technologies. E-mail Doug Macron or follow his GenomeWeb Twitter account at @Genesilencing. |
TransDerm Preps for New Phase I Trial with New RNAi Drug, Delivery System
June 07, 2012
TransDerm Preps for New Phase I Trial with New RNAi Drug, Delivery System
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- TransDerm Awarded $4M Grant to Develop RNAi Treatment for Skin Disease
September 29, 2011 / Gene Silencing News - TransDerm Inks Research Deal with RXi, Gets Grant to Explore Delivery Technologies
April 8, 2010 / Gene Silencing News - TransDerm Team Reports on Imaging Method for siRNA Delivery Tech Screening
November 8, 2012 / Gene Silencing News - Isis Exec Sees Antisense as Third Major Drug Platform, Says More Work to Be Done
April 19, 2012 / Gene Silencing News - Choosing Skin and Eye Disorders, RXi Will Face Well-Worn R&D Paths
June 17, 2010 / Gene Silencing News